<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845894</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00055981</org_study_id>
    <nct_id>NCT03845894</nct_id>
  </id_info>
  <brief_title>Interscalene Block With Liposomal Bupivacaine vs. Interscalene Block With Bupivacaine and Adjuvants</brief_title>
  <official_title>Single Injection Interscalene Brachial Plexus Nerve Block With Adjuvants vs. Liposomal Bupivacaine Interscalene Brachial Plexus Nerve Block for Total Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the use of plain bupivacaine with common
      adjuvants for interscalene block (ISB) provides non-inferior analgesic results compared to
      the use of liposomal bupivacaine for ISB, in patients undergoing total shoulder arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this clinical study is to evaluate the comparative efficacy of
      interscalene block (ISB) using plain bupivacaine with adjuvants vs. liposomal bupivacaine on
      mean postoperative pain levels in patients who have undergone a total shoulder arthroplasty
      within the first 48 hours. Principal Investigators hypothesize that ISB using plain
      bupivacaine with adjuvants will provide similar pain relief as ISB using liposomal
      bupivacaine.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-under-the-curve (AUC) of average pain scores for the first 48 hours</measure>
    <time_frame>Up to 48 hours postoperatively</time_frame>
    <description>Pain levels will be measured by the mean Visual Analogue Scale- Numeric Rating Scale (VAS-NRS). The VAS-NRS is an 11 point scale with 0 (no pain) to 10 (worst possible pain). Higher scores denote worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average pain score at 48 hours</measure>
    <time_frame>at 48 hours</time_frame>
    <description>Pain levels will be measured by the mean VAS-NRS. The VAS-NRS is an 11 point scale with 0 (no pain) to 10 (worst possible pain). Higher scores denote worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid consumption for the first 48 hours</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Opioid consumption will be reported as the mean in PO oxycodone equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with surgical experience</measure>
    <time_frame>At 48 hours</time_frame>
    <description>Satisfaction levels will be measured by questionnaire on a5 point Likert scale with 1 (Strong Disagree) to 5 (Strongly Agree). Higher scores denote better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Shoulder Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine ISB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine with adjuvants ISB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)</description>
    <arm_group_label>Liposomal Bupivacaine ISB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine with adjuvants</intervention_name>
    <description>Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.</description>
    <arm_group_label>Bupivacaine with adjuvants ISB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing total shoulder arthroplasty (not a reverse)

          -  Age â‰¥ 18 years

          -  Ability to understand and the willingness to sign an IRB-approved informed consent
             document.

          -  ASA patient status I-III patients

          -  Weight Greater than or equal to 50 kg

        Exclusion Criteria:

          -  Contraindications to an interscalene block or phrenic blockade

          -  Infection at injection site

          -  Pre-existing neurological dysfunction affecting the operative extremity

          -  Chronic pain diagnosis or opioid use &gt;40mg oxycodone daily equivalents or use of
             long-acting opioids

          -  BMI &gt;40

          -  Uncontrolled diabetes (A1c &gt;8.0)

          -  Concurrent painful physical condition requiring analgesic treatment (eg, NSAID or
             opioid) in the postsurgical period for pain not strictly related to the surgery

          -  Contraindications to any pain-control agents planned for surgical or postsurgical use
             (i.e., bupivacaine, hydromorphone, etc.)

          -  Patients who are wards of the state

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to bupivacaine or liposomal bupivacaine.

          -  Patients with moderate-severe hepatic or renal impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doug Jaffe, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sakamoto B, Keiser S, Meldrum R, Harker G, Freese A. Efficacy of Liposomal Bupivacaine Infiltration on the Management of Total Knee Arthroplasty. JAMA Surg. 2017 Jan 1;152(1):90-95. doi: 10.1001/jamasurg.2016.3474.</citation>
    <PMID>27732710</PMID>
  </reference>
  <reference>
    <citation>Hamilton TW, Athanassoglou V, Mellon S, Strickland LH, Trivella M, Murray D, Pandit HG. Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. Cochrane Database Syst Rev. 2017 Feb 1;2:CD011419. doi: 10.1002/14651858.CD011419.pub2. Review.</citation>
    <PMID>28146271</PMID>
  </reference>
  <reference>
    <citation>Pichler L, Poeran J, Zubizarreta N, Cozowicz C, Sun EC, Mazumdar M, Memtsoudis SG. Liposomal Bupivacaine Does Not Reduce Inpatient Opioid Prescription or Related Complications after Knee Arthroplasty: A Database Analysis. Anesthesiology. 2018 Oct;129(4):689-699. doi: 10.1097/ALN.0000000000002267.</citation>
    <PMID>29787389</PMID>
  </reference>
  <reference>
    <citation>Hamilton TW, Athanassoglou V, Trivella M, Strickland LH, Mellon S, Murray D, Pandit HG. Liposomal bupivacaine peripheral nerve block for the management of postoperative pain. Cochrane Database Syst Rev. 2016 Aug 25;(8):CD011476. doi: 10.1002/14651858.CD011476.pub2. Review.</citation>
    <PMID>27558150</PMID>
  </reference>
  <reference>
    <citation>Rabin T. FDA In Brief: FDA approves new use of Exparel for nerve block pain relief following shoulder surgeries.</citation>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shoulder Replacement Surgery</keyword>
  <keyword>Interscalene Nerve Block</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <keyword>Shoulder pain</keyword>
  <keyword>Regional anesthesia</keyword>
  <keyword>Brachial plexus blockade</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will be shared upon request: raw data and statistical calculations</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Available after study conclusion, for up to 3 years afterward.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

